EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a gene editing company with a versatile portfolio of next-generation CRISPR gene editing tools, today announced its participation in the following investor and industry conferences: Chardan’s 6th Annual Genetic Medicines Conference – New York City Corporate presentation, 9:00 – 9:25 a.m. EDT, followed by a panel presentation on next-generation gene editing, 9:30 … [Read more…]

Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC … [Read more…]

PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (“SVV-001”) in combination with a checkpoint inhibitor. This Phase I/II study with SVV-001 is in patients … [Read more…]

– Villaris shareholders to receive upfront payment of $70 million, with potential for up to $1.36 billion in additional milestone payments – Pre-clinical data for auremolimab demonstrate high potency, selectivity and efficacy in vitiligo – Acquisition will complement Incyte’s existing Inflammation and AutoImmunity portfolio with potential applications for auremolimab beyond Dermatology WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (NASDAQ:INCY) … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Sleep Apnea Device Market Research and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global sleep apnea device market is growing at a considerable CAGR of 7.8% during the forecast period. Increasing pervasiveness of cardiovascular diseases and growing innovation and development of new products are estimated to be the prime … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Glaucoma treatment Market Research and Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global glaucoma treatment market is anticipated to grow at a considerable CAGR of 5.2% during the forecast period (2021-2027). Glaucoma is one of the major eye disorders which causes damage to the optic nerve and can cause … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Glycomics Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. The Glycomics Market is evaluated at US$1,174.889 million for the year 2022, growing at a CAGR of 8.63%, reaching the market size of US$2,096.655 million by the year 2027. The global glycomics market is anticipated to propel at … [Read more…]

Hyperthermia system made in Japan, benefitting cancer patients, attracts the interest of overseas cancer hospitals. TOKYO–(BUSINESS WIRE)–Treatment of cancer using one’s own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional chemotherapy, radiotherapy and surgery, practiced in Japan for long is now offered in Vinmec … [Read more…]

TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study: Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction of 13.7% after three months and 14.3% after six months, compared to placebo. A very … [Read more…]

Completion of preclinical studies support potential to advance PXL770 into Phase 2 development for ADPKD Compelling preclinical efficacy data confirm strategic focus for PXL770 in rare metabolic diseases LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis … [Read more…]